Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Transient neurones match the spontaneous and sensory driven activities to shape cortical circuits: a landmark collaborative review published in Science from Professor Zoltán Molnár, Professor Patrick Kanold and Professor Heiko Luhmann.

Overlayed silhouttes of adult, adolescent, infant and baby craniums, highlighting neuronal circuits in their brains © Professor Zoltán Molnár

A new collaborative review between Department of Physiology, Anatomy & Genetics's Professor Zoltán Molnár, Professor Patrick Kanold (Johns Hopkins University Department of Biomedical Engineering and Kavli Neuroscience Discovery Institute) and Professor Heiko Luhmann (University Medical Center of the Johannes Gutenberg University Mainz) gives a comprehensive overview of the transient neuronal circuits in both the cerebral cortex and in the thalamus, the circuits that relay and process most of the information from our sensory environment.

The paper comes in response to the last two decades of developmental neuroscience research, during which a major focus has been on genetics, whereas the fundamentally important role of electrical activity from the earliest stages of brain development has only recently become evident. This review draws from each author’s research across the last three decades to demonstrate that during early development of the mammalian brain, transient neuronal populations integrate spontaneous and externally generated activity patterns to form mature cortical networks.

The full story is available on the Department of Physiology, Anatomy & Genetics website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.